Research Article
Impairment of Quality of Life among Patients with Wearable Cardioverter Defibrillator Therapy (LifeVest®): A Preliminary Study
Table 1
Patient’s characteristics.
| | | All patients | ICM | DCM | Others |
| | n | 109 | 46 (42%) | 47 (43%) | 16 (15%) | | Age (years) | 58 ± 16 | 68 ± 16 | 54 ± 16 | 44 ± 16 | | Male sex (%) | 85 (78%) | 42 (91%) | 34 (72%) | 9 (56%) | | After acute myocardial infarction | 16 (15%) | 16 (35%) | 0 | 0 | | LV-EF (%) | 32 ± 14 | 36 ± 15 | 26 ± 9 | 38 ± 17 | | Indication | | Primary prophylactic | 81 (74%) | 29 (63%) | 42 (89%) | 10 (63%) | | Secondary prophylactic | 38 (26%) | 17 (37%) | 5 (11%) | 6 (37%) | | Functional status | | NYHA I | 11 (10%) | 7 (15%) | 1 (2%) | 3 (19%) | | NYHA II | 44 (40%) | 23 (50%) | 15 (32%) | 5 (31%) | | NYHA III | 44 (40%) | 16 (35%) | 22 (47%) | 6 (37%) | | NYHA IV | 9 (8%) | 0 (0%) | 8 (17%) | 1 (6%) | | Cardiovascular risk factors | | Diabetes mellitus | 30 (28%) | 17 (37%) | 11 (23%) | 2 (13%) | | Smoking | 48 (44%) | 24 (52%) | 18 (38%) | 6 (38%) | | Hypercholesterolaemia | 52 (48%) | 32 (70%) | 16 (34%) | 4 (25%) | | Hypertension | 55 (50%) | 34 (73%) | 17 (36%) | 4 (25%) | | Creatinine (mg/dl) | 1.2 ± 0.6 | 1.2 ± 0.6 | 1.3 ± 0.6 | 1.0 ± 0.6 | | Current medication | | Beta blocker | 103 (94%) | 45 (98%) | 45 (96%) | 13 (81%) | | Inhibitors of ACE or AR | 95 (87%) | 42 (91%) | 42 (89%) | 11 (69%) | | Diuretics | 86 (79%) | 32 (70%) | 45 (96%) | 9 (57%) | | Aldosterone antagonist | 85 (78%) | 34 (74%) | 41 (87%) | 10 (63%) | | Amiodarone | 7 (6%) | 2 (4%) | 5 (11%) | 0 (0%) |
|
|
NYHA: New York heart association, ACE: angiotensin converting enzyme, AR: angiotensin receptor.
|
